Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts. Group revenues totalled $45.8bn last year, up 6% at constant exchange rates from the $44.4bn generated in 2022. Excluding Covid-19 medicines, growth would have been 15%.

The company saw a particularly strong performance in Oncology, where sales of cancer drugs jumped 21% to $18.5bn, and also saw double-digit growth in Cardiovascular, Renal and Metabolism (+18%), Respiratory & Immunology (+10%), and Rare Disease (+12%).

Core earnings per share were up 15% on the year at $7.26, but fourth-quarter core EPS rose by a lesser 7% to $1.45, which was a 3% miss against consensus forecasts.

The stock was down 2.2% at 10,260p in early trading on Thursday.

Looking ahead to the 2024 financial year, total revenues and core EPS are expected to increase by a low double-digit to low teens percentage at constant exchange rates.

"We expect another year of strong growth in 2024, driven by continued adoption of our medicines across geographies," said chief executive Pascal Soriot.

"Our differentiated and growing portfolio of approved medicines, global reach and rich R&D pipeline give us confidence that we will continue to deliver industry-leading growth."

Share this article

Related Sharecast Articles

SigmaRoc delivers 'solid' Q1 performance
(Sharecast News) - Limestone group SigmaRoc said on Friday that it had delivered a "solid Q1 performance", with underlying earnings in line with management expectations.
Samsung in line to secure $6bn in US government grants
(Sharecast News) - Electronics giant Samsung will unveil a $44.0bn White House programme aimed at bringing semiconductor production back to America as soon as next week, with the memory chip maker in line to secure up to $6.0bn in government grants.
BAE Systems 'still riding high', says Deutsche Bank
(Sharecast News) - Deutsche Bank has hiked its target price for BAE Systems and maintained a 'buy' rating on the aerospace and defence stock, saying that recent growth momentum is likely to continue.
Societe Generale sells Moroccan unit to Saham Group
(Sharecast News) - French bank Societe Generale has agreed to sell the majority of its Moroccan arm to Saham Group for €745.0m as it forges ahead with chief executive Slawomir Krupa's plan to streamline the business.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.